论文部分内容阅读
目的:研究分析痰热清注射液治疗成人重症肺炎的治疗效果及安全性。方法:在Cochrane Library、Medline、Embase、OVID、VIP和CNKI-中国期刊全文数据库(1980—2015年)中检索2015-08-01之前对国内外公开发表的有关于痰热清注射液治疗成人重症肺炎的临床疗效随机对照临床试验文献(randomized clinical trial,RCT)。采用Jadad质量评分标准进行评价,对纳入的文献采用Review Manager 5.3软件进行Meta分析。结果:共纳入10篇随机对照试验,共762例患者符合纳入标准,纳入本Meta分析。Meta分析结果显示:经齐性检验,纳入7篇研究具有同质性(χ~2=3.49,P=0.75,I2=0),采用固定效应模式,结果显示痰热清注射液组治疗成人重症肺炎的治愈率优于对照组,综合优势比(OR)为0.49,95%可信区间为(0.31,0.76),整体效益检验Z=3.14,P<0.002;纳入10篇研究具有同质性(χ~2=7.16,P=0.62,I2=0),采用固定效应模式,结果显示痰热清注射液组治疗成人重症肺炎的总有效率优于对照组,综合优势比(OR)为0.31,95%可信区间为(0.21,0.47),整体效益检验Z=5.56,P<0.00001。结论:经有限的证据显示,痰热清注射液治疗成人重症肺炎具有良好的治疗效果及安全性,在临床治疗中具有重要作用。因本次研究缺乏高质量的随机对照研究,因此应用痰热清注射液治疗成人重症肺炎具有良好的治疗效果及安全性还需要更多的高质量临床研究来予以进一步证实。
Objective: To study the effect and safety of Tanreqing Injection in treating severe pneumonia in adults. METHODS: The Cochrane Library, Medline, Embase, OVID, VIP and CNKI-CNKI Chinese Journal Full-text Database (1980-2015) were retrieved before 2015-08-01. The domestic and international public published reports about Tanreqing Injection Clinical efficacy of pneumonia Randomized clinical trial (RCT). The Jadad quality score was used for evaluation. Meta-analysis was performed on the included articles using Review Manager 5.3 software. Results: A total of 10 randomized controlled trials were included. A total of 762 patients met the inclusion criteria and were included in this meta-analysis. Results of Meta-analysis showed that homogeneity was found in 7 of the 7 studies (χ ~ 2 = 3.49, P = 0.75, I2 = 0). The fixed effects model was used. The results showed that Tanreqing Injection The cure rate of pneumonia was better than that of the control group, with a comprehensive odds ratio (OR) of 0.49, 95% confidence interval (0.31, 0.76), overall benefit test Z = 3.14, P <0.002; The results showed that the total effective rate of Tanreqing injection group for treating severe pneumonia in adults was better than that of the control group, and the overall odds ratio (OR) was 0.31, 95% confidence interval (0.21,0.47), the overall benefit test Z = 5.56, P <0.00001. Conclusion: The limited evidence shows that Tanreqing injection in the treatment of severe pneumonia in adults has good therapeutic effect and safety, and plays an important role in clinical treatment. Because of the lack of high-quality randomized controlled studies in this study, the application of Tanreqing Injection in the treatment of severe pneumonia in adults has good therapeutic effect and safety. More high-quality clinical studies are needed to further confirm this.